https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Opdivo-nivolumab-plus-Yervoy-ipilimumab-for-the-First-Line-Treatment-of-Adult-Patients-with-Microsatellite-InstabilityHigh-or-Mismatch-Repair-Deficient-Metastatic-Colorectal-Cancer/default.aspx